Sanofi And Regeneron Report Positive Proof-of-Concept Data For Dupilumab, An IL-4R Alpha Antibody, In Atopic Dermatitis

New Drug Approvals

Monoclonal antibody
Source Human
Target IL4 receptor alpha

 

Treatment of atopic diseases

Immunoglobulin, anti-(human interleukin 4 receptor α) (human REGN668 heavy chain),
disulfide with human REGN668 κ-chain, dimer

Immunoglobulin G4, anti-(human interleukin-4 receptor subunit alpha (IL-4R-alpha,
CD124)); human monoclonal REGN668 des-452-lysine{CH3107K>-}-[233-
proline{H10S>P}]γ4 heavy chain (139-219′)-disulfide with human monoclonal REGN668
κ light chain, dimer (231-231”:234-234”)-bisdisulfide

1190264-60-8 cas no

REGN668, SAR231893

MOLECULAR FORMULA- C6512H10066N1730O2052S46

Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases.[1]

This drug was developed by Regeneron Pharmaceuticals.

  1. Statement On A Nonproprietary Name Adopted By The USAN Council – Dupilumab,American Medical Association.

Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatology

PARIS and TARRYTOWN, N.Y., March 2, 2013  – Sanofi and Regeneron Pharmaceuticals, Inc.  today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the…

View original post 874 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s